Thomas B. Richards
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thomas B. Richards has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Mary C. White
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, USA
4 shared publications - Sarah Jane Henley
Division of Cancer Prevention and Control National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention Atlanta Georgia USA
4 shared publications Susan A. Sabatino
National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), Chamblee, GA
4 shared publicationsXingyou Zhang
U.S. Bureau of Labor Statistics, Washington, DC
4 shared publications- Zahava Berkowitz
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
4 shared publications Cheryll C. Thomas
3 shared publications
Latest Publications
- 22 September 2026
- Published by SAGE Publications in Journal of Women's Health
Building Computable Guidelines and Clinical Decision Support Tools for Cervical, Breast and Colorectal Cancer Screening and Risk Management: A CDC Initiative Update
Background: Clinical practice guidelines for cancer screening and management are developed by multiple guideline organizations and published in narrative form. However, guideline concordance can be challenging due to several factors: rapid advances in cancer care, increasing complexity of narrative clinical guidelines, and the unstructured nature of information needed for decisions in electronic health records (EHRs). Clinical decision support (CDS) tools, or computer-interpretable versions of clinical practice guidelines, may help address these challenges when provided to clinicians at the point of care. Materials and Methods: The Centers for Disease Control and Prevention collaborated with MITRE Corporation and subject matter experts to translate current narrative guidelines for cervical, breast, and colorectal cancer screening and management into standards-based computable guidelines and interoperable CDS tools. The tools apply guideline logic in real-time to patient EHR data to assess screening history and risk and generate recommended actions. Results: Computable guidelines and CDS tools were developed for all three cancers. The cervical cancer CDS was integrated into EHRs and underwent a 6-month clinical pilot evaluation. Breast and colorectal cancer CDS tools progressed to executable code tested with synthetic patient data but have not undergone clinical pilot testing. All three CDS tools are open source, with code available for download. Conclusions: Standards-based computable guidelines can support implementation of complex cancer screening and management recommendations within EHRs. Further development and implementation will require improved structured data capture, interoperable workflows, and sustained support. All three CDS tools require longer-term evaluation to assess usability, acceptability, and clinical outcomes.
- 22 September 2026
- Published by SAGE Publications in Journal of Women's Health
Building Computable Guidelines and Clinical Decision Support Tools for Cervical, Breast and Colorectal Cancer Screening and Risk Management: A CDC Initiative Update
Background: Clinical practice guidelines for cancer screening and management are developed by multiple guideline organizations and published in narrative form. However, guideline concordance can be challenging due to several factors: rapid advances in cancer care, increasing complexity of narrative clinical guidelines, and the unstructured nature of information needed for decisions in electronic health records (EHRs). Clinical decision support (CDS) tools, or computer-interpretable versions of clinical practice guidelines, may help address these challenges when provided to clinicians at the point of care. Materials and Methods: The Centers for Disease Control and Prevention collaborated with MITRE Corporation and subject matter experts to translate current narrative guidelines for cervical, breast, and colorectal cancer screening and management into standards-based computable guidelines and interoperable CDS tools. The tools apply guideline logic in real-time to patient EHR data to assess screening history and risk and generate recommended actions. Results: Computable guidelines and CDS tools were developed for all three cancers. The cervical cancer CDS was integrated into EHRs and underwent a 6-month clinical pilot evaluation. Breast and colorectal cancer CDS tools progressed to executable code tested with synthetic patient data but have not undergone clinical pilot testing. All three CDS tools are open source, with code available for download. Conclusions: Standards-based computable guidelines can support implementation of complex cancer screening and management recommendations within EHRs. Further development and implementation will require improved structured data capture, interoperable workflows, and sustained support. All three CDS tools require longer-term evaluation to assess usability, acceptability, and clinical outcomes.
The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance
Background: Recent advancements in the clinical management of metastatic prostate cancer include several costly therapies and diagnostic tests. The objective of this study was to provide updated information on the cost to payers attributable to metastatic prostate cancer among men aged 18 to 64 years with employer‐sponsored health plans and men aged 18 years or older covered by employer‐sponsored Medicare supplement insurance.Methods: By using Merative MarketScan commercial and Medicare supplemental data for 2009–2019, the authors calculated differences in spending between men with metastatic prostate cancer and their matched, prostate cancer‐free controls, adjusting for age, enrollment length, comorbidities, and inflation to 2019 US dollars.Results: The authors compared 9011 patients who had metastatic prostate cancer and were covered by commercial insurance plans with a group of 44,934 matched controls and also compared 17,899 patients who had metastatic prostate cancer and were covered by employer‐sponsored Medicare supplement plans with a group of 87,884 matched controls. The mean age of patients with metastatic prostate cancer was 58.5 years in the commercial samples and 77.8 years in the Medicare supplement samples. Annual spending attributable to metastatic prostate cancer was $55,949 per person‐year (95% confidence interval [CI], $54,074–$57,825 per person‐year) in the commercial population and $43,682 per person‐year (95% CI, $42,022–$45,342 per person‐year) in the population covered by Medicare supplement plans, both in 2019 US dollars.Conclusions: The cost burden attributable to metastatic prostate cancer exceeds $55,000 per person‐year among men with employer‐sponsored health insurance and $43,000 among those covered by employer‐sponsored Medicare supplement plans. These estimates can improve the precision of value assessments of clinical and policy approaches to the prevention, screening, and treatment of prostate cancer in the United States.
The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance
Background: Recent advancements in the clinical management of metastatic prostate cancer include several costly therapies and diagnostic tests. The objective of this study was to provide updated information on the cost to payers attributable to metastatic prostate cancer among men aged 18 to 64 years with employer‐sponsored health plans and men aged 18 years or older covered by employer‐sponsored Medicare supplement insurance.Methods: By using Merative MarketScan commercial and Medicare supplemental data for 2009–2019, the authors calculated differences in spending between men with metastatic prostate cancer and their matched, prostate cancer‐free controls, adjusting for age, enrollment length, comorbidities, and inflation to 2019 US dollars.Results: The authors compared 9011 patients who had metastatic prostate cancer and were covered by commercial insurance plans with a group of 44,934 matched controls and also compared 17,899 patients who had metastatic prostate cancer and were covered by employer‐sponsored Medicare supplement plans with a group of 87,884 matched controls. The mean age of patients with metastatic prostate cancer was 58.5 years in the commercial samples and 77.8 years in the Medicare supplement samples. Annual spending attributable to metastatic prostate cancer was $55,949 per person‐year (95% confidence interval [CI], $54,074–$57,825 per person‐year) in the commercial population and $43,682 per person‐year (95% CI, $42,022–$45,342 per person‐year) in the population covered by Medicare supplement plans, both in 2019 US dollars.Conclusions: The cost burden attributable to metastatic prostate cancer exceeds $55,000 per person‐year among men with employer‐sponsored health insurance and $43,000 among those covered by employer‐sponsored Medicare supplement plans. These estimates can improve the precision of value assessments of clinical and policy approaches to the prevention, screening, and treatment of prostate cancer in the United States.
- 1 January 2023
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 10 (1) , 41-47
The Cost of Metastatic Prostate Cancer in the United States
Introduction:We sought to estimate per patient and annual aggregate health care costs related to metastatic prostate cancer.Methods:Using the Surveillance, Epidemiology, and End Results-Med...
- 1 January 2023
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 10 (1) , 41-47
The Cost of Metastatic Prostate Cancer in the United States
Introduction:We sought to estimate per patient and annual aggregate health care costs related to metastatic prostate cancer.Methods:Using the Surveillance, Epidemiology, and End Results-Med...
- 10 March 2022
- Published by Elsevier in Preventive Medicine
- Vol. 159, 107019
Human papilloma virus vaccination and cervical cancer screening coverage in managed care plans — United States, 2018
- 10 March 2022
- Published by Elsevier in Preventive Medicine
- Vol. 159, 107019
Human papilloma virus vaccination and cervical cancer screening coverage in managed care plans — United States, 2018
- 27 February 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (5) , 192.e19-192.e25
Number of prostate-specific antigen (PSA) screening tests in the last five years reported by men in the United States in 2010, 2015, and 2018
- 27 February 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (5) , 192.e19-192.e25
Number of prostate-specific antigen (PSA) screening tests in the last five years reported by men in the United States in 2010, 2015, and 2018
- 1 February 2022
- Published by Elsevier in Annals of Epidemiology
- Vol. 66, 20-27
Multilevel small area estimation for county-level prevalence of colorectal cancer screening test use in the United States using 2018 data
- 1 February 2022
- Published by Elsevier in Annals of Epidemiology
- Vol. 66, 20-27
Multilevel small area estimation for county-level prevalence of colorectal cancer screening test use in the United States using 2018 data
- Open Access
- 1 May 2021
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 34 (3) , 634-647
Multilevel Small Area Estimation of Prostate-Specific Antigen Screening Test in the United States by Age Group: 2018 Behavioral Risk Factor Surveillance System
Background: In 2018, the US Preventive Services Task Force (USPSTF) recommended prostate cancer screening for men aged 55 to 69 years who express a preference for being screened after being informed about and understanding prostate-specific antigen (PSA) test benefits and risks. USPSTF recommended against screening men aged ≥70 years. We aim to generate county-level prevalence estimates, masked by national and state estimates, to identify counties with high PSA screening prevalence. Methods: We fitted multilevel logistic regression mixed models for 4 age groups (≥40, 40 to 54, 55 to 69, ≥70 years), using data from the 2018 Behavioral Risk Factor Surveillance System (BRFSS) (n = 116,654) and other sources. We evaluated consistency between our model-based state and BRFSS direct state estimates with Spearman and Pearson correlation coefficients. Results: PSA screening prevalence increased with increasing age groups: 7.7% for men aged 40 to 54 years, 27.2% for men aged 55 to 69 years, and 33.7% among men age ≥70 years, and was largely clustered in the South and Appalachia. Many county estimates among men aged ≥70 years exceeded 40%, especially in the South. Correlation coefficients were 0.94 for men aged ≥40, and ≥0.85 for men aged 40 to 54 years, 55 to 69 years, and ≥70 years. Conclusions: PSA screening was highest among men ≥70 years, for whom it is not recommended, and in the South among all age groups. Screening varied substantially within states. Impact: In 2018, on average, more than 1 in 4 men aged 55 to 69 years and 1 in 3 men aged ≥70 years underwent PSA screening in the prior year, suggesting potential overuse among some men.
- 1 May 2021
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 34 (3) , 634-647
Open AccessMultilevel Small Area Estimation of Prostate-Specific Antigen Screening Test in the United States by Age Group: 2018 Behavioral Risk Factor Surveillance System
Background: In 2018, the US Preventive Services Task Force (USPSTF) recommended prostate cancer screening for men aged 55 to 69 years who express a preference for being screened after being informed about and understanding prostate-specific antigen (PSA) test benefits and risks. USPSTF recommended against screening men aged ≥70 years. We aim to generate county-level prevalence estimates, masked by national and state estimates, to identify counties with high PSA screening prevalence. Methods: We fitted multilevel logistic regression mixed models for 4 age groups (≥40, 40 to 54, 55 to 69, ≥70 years), using data from the 2018 Behavioral Risk Factor Surveillance System (BRFSS) (n = 116,654) and other sources. We evaluated consistency between our model-based state and BRFSS direct state estimates with Spearman and Pearson correlation coefficients. Results: PSA screening prevalence increased with increasing age groups: 7.7% for men aged 40 to 54 years, 27.2% for men aged 55 to 69 years, and 33.7% among men age ≥70 years, and was largely clustered in the South and Appalachia. Many county estimates among men aged ≥70 years exceeded 40%, especially in the South. Correlation coefficients were 0.94 for men aged ≥40, and ≥0.85 for men aged 40 to 54 years, 55 to 69 years, and ≥70 years. Conclusions: PSA screening was highest among men ≥70 years, for whom it is not recommended, and in the South among all age groups. Screening varied substantially within states. Impact: In 2018, on average, more than 1 in 4 men aged 55 to 69 years and 1 in 3 men aged ≥70 years underwent PSA screening in the prior year, suggesting potential overuse among some men.
- 28 February 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (8) , 201-206
Screening for Lung Cancer — 10 States, 2017
Many adults who meet the criteria to be screened for lung cancer do not report recommended screening. Efforts to educate health care providers and patients might increase appropriate lung cancer screening.
- 28 February 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (8) , 201-206
Screening for Lung Cancer — 10 States, 2017
Many adults who meet the criteria to be screened for lung cancer do not report recommended screening. Efforts to educate health care providers and patients might increase appropriate lung cancer screening.
- 6 January 2020
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 35 (7) , 2207-2209
Women’s Reports of Dense Breast Notification Following Mammography: Findings from the 2015 National Health Interview Survey
- 6 January 2020
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 35 (7) , 2207-2209
Women’s Reports of Dense Breast Notification Following Mammography: Findings from the 2015 National Health Interview Survey
- 1 January 2019
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 56 (1) , 66-73
Lung Cancer Screening Inconsistent With U.S. Preventive Services Task Force Recommendations
- 1 January 2019
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 56 (1) , 66-73
Lung Cancer Screening Inconsistent With U.S. Preventive Services Task Force Recommendations